Hypothermia
DeviceInduced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 72 hours
NCT Number: NCT01793129
This study is a randomized, controlled trial to assess safety and effectiveness of whole body hypothermia for 72 hours in preterm infants 33-35 weeks gestational age (GA) who present at <6 hours postnatal age with moderate to severe neonatal encephalopathy (NE). The study will enroll infants with signs of NE at 18 NICHD Neonatal Research Network sites, and randomly assign them to either receive hypothermia or participate in a non-cooled control group.
Looking for future studies?
Notify Me33 week–35 week
All sexes
Interventional
Not applicable
University of Alabama at Birmingham, Birmingham, Alabama, United States
Most clinical studies of neonatal encephalopathy (NE) and potential interventions have focused on infants ≥36 weeks GA. Although many interventions have been suggested and assessed for prevention or palliation of NE, the only one currently supported by rigorous clinical evidence to improve outcome in human newborns has been hypothermia implemented at <6 hours of postnatal age and maintained for 72 hrs. Data about diagnosis, frequency, severity, and outcome of NE in infants 33-35 weeks GA are sparse.
This trial will assess safety and effectiveness of whole body hypothermia for 72 hours in preterm infants 33-35 weeks gestational age (GA) who present at <6 hrs postnatal age with moderate to severe neonatal encephalopathy. Infants 33 0/7 to 35 6/7 weeks GA (best obstetrical estimate) and greater than or equal to 1500 grams birth weight (selected to minimize potential difficulties placing esophageal probe) who meet clinical, biochemical and neurologic criteria for moderate to severe NE will be randomized to either whole body hypothermia or participate in a non-cooled control group. The primary outcome will be death or moderate to severe disability at 18-22 months corrected age. The presence or absence of disability will be determined by the standard NRN interdisciplinary follow-up exam.
Secondary Study includes determining an association between MRI detectable injury and neurodevelopment at 18-22 months.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Biochemical: Cord gas or blood gas within first hour of life with pH ≤7.00 or base deficit (BD) ≥16 mEq/L OR
Acute perinatal event (e.g., abruptio placenta, cord prolapse, uterine rupture, severe FHR abnormality such as variable or late decelerations) AND Requirement for positive pressure ventilation for apnea or poor respiratory effort since birth for at least 10 minutes OR 10 minute Apgar score ≤5
AND
Neurologic:
Seizures OR modified Sarnat score with abnormalities in at least 3 of the 6 categories; at least one must be altered level of consciousness (lethargy or stupor/coma) as determined by a certified examiner (All infants who meet criteria for potential inclusion will undergo standard neurologic exam as for infants ≥36 wks GA being considered for hypothermia, with findings recorded)
Exclusion criteria
Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 72 hours
Normothermic Control group (with esophageal temperature at or near 37.0°C) for 96 hours
Time frame: Birth to 18-22 months corrected age
Severe disability was defined by any of the following: a Bayley III cognitive score < 70 or Gross Motor Function (GMF) Level of 3-5 blindness or profound hearing loss requiring amplification but still unable to following commands/communicate. Moderate disability was defined as a Bayley III cognitive score between 70-84 and either a GMF level of 2 or a seizure disorder or a hearing deficit.
Time frame: Birth to 18-22 months corrected age
Number of deaths in the NICU and following discharge among infants with a primary outcome.
Time frame: Post-intervention to through discharge, death, or transfer (whichever comes first), average of 29 days
An MRI was considered abnormal if any abnormal findings were indicated on the CRF form.
Time frame: Birth to 18-22 months corrrected age
Number of infants with moderate or severe disability among survivors through 18-22 months corrected age.
Time frame: Birth to 18-22 months corrrected age
Causes of any deaths that occurred through 18-22 months corrected age.
Time frame: Within 6 hours of life to 72 hours after start of intervention
Infants with recorded events of intraventricular hemorrhage grade I, II, III, or IV, posterior fossa hemorrhage with/without shift of midline structures, intraparenchymal hemorrhage.
NICHD Neonatal Research Network
Network
A Randomized Trial of Targeted Temperature Management With Whole Body Hypothermia For Moderate And Severe Hypoxic-Ischemic Encephalopathy In Premature Infants 33-35 Weeks Gestational Age.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00614744
Body Temperature Changes, Brain Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT00005772
Body Temperature Changes, Brain Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT03278847
Asphyxia Neonatorum, Body Temperature Changes
London, United Kingdom
View Trial DetailsNCT01534481
Female Urogenital Diseases and Pregnancy Complications, Infant, Extremely Low Birth Weight
Birmingham, Alabama, United States
View Trial Details